SNU-761 Cells
USUSD$540.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
一般資訊
| 說明 | The SNU-761 cell line is a human hepatocellular carcinoma (HCC) model derived from an adult patient. As part of the Cancer Cell Line Encyclopedia (CCLE) and LIMORE (Liver Cancer Model Repository) initiatives, SNU-761 has been extensively characterized at multiple molecular levels. The cell line has been used to explore the genetic and transcriptomic heterogeneity typical of primary liver cancers, including those associated with hepatitis B virus (HBV) infection, which is prevalent in many East Asian HCC cases. Genomic profiling has revealed that LIMORE models such as SNU-761 often retain the mutational and copy number alteration landscapes of primary tumors, including alterations in key oncogenic drivers like TP53, CTNNB1, and FGF19. SNU-761 and other liver cancer models in the LIMORE collection have undergone high-throughput drug sensitivity screening across a wide panel of chemotherapeutics and targeted agents. These pharmacogenomic datasets have allowed researchers to identify potential biomarkers predictive of response, such as gene-drug associations and synthetic lethalities relevant to common mutations in liver cancer. Furthermore, comparisons of transcriptomic and epigenetic data—such as DNA methylation and histone modification patterns—have helped classify SNU-761 within liver cancer subtypes and assess its functional attributes, including invasiveness and response to pathway-specific inhibitors. This extensive profiling makes SNU-761 a valuable model for studying HBV-related HCC and evaluating personalized therapeutic strategies. |
|---|---|
| 生物體 | Human |
| 組織 | Liver |
| 疾病 | hepatocellular carcinoma |
| 同義詞 | SNU761, NCI-SNU-761 |
特徵
| 年齡 | 49 years |
|---|---|
| 性別 | Male |
| 族裔 | Korean |
| 形態學 | Polygonal |
| 細胞類型 | Epithelial |
| 生長特性 | Adherent, monolayer |
監管數據
| 引用 | SNU-761 (Cytion catalog number 305637) |
|---|---|
| 生物安全等級 | 2 |
| NCBI_TaxID | 9606 |
| Cellosaurus 編號 | CVCL_5089 |
生物分子資料
| 突變譜 | Mutation: TP53, Simple, p.Ser313Glyfs*13 (c.937_968delAGCTCCTCTCCCCAGCCAAAGAAGAAACCACT), Unspecified |
|---|
處理方式
| 培養基 | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| 營養補充品 | Supplement the medium with 10% heat-inactivated FBS, add 2.5 g/L glucose and 10 mM HEPES |
| 解離試劑 | Accutase |
| 倍增時間 | 24 hours |
| 傳代培養 | Remove medium, add fresh 0.25 % trypsin 0.02 % EDTA solution, stand culture flask at 37''''C for 3 to 5 minutes, add culture medium and collect the cells, transfer the medium into 15ml tube, centrifuge, aspirate the medium, resuspend the pellets with culture medium and dispense into the culture flask |
| 播種密度 | 1 to 3 x 104 cells/cm2 |
| 流體更新 | 2 to 3 times per week |
| 冷凍培養基 | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| 細胞解凍與培養 |
|
| 培養環境 | 37°C, 5% CO2, humidified atmosphere. |
| 運送條款 | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| 儲存條件 | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
品質控制與分子分析
| 不孕症 | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
分析證明書 (CoA)
| 批次編號 | 證書類型 | 日期 | 型號 |
|---|---|---|---|
| 305637-200426 | 分析證明書 | 22. May. 2026 | 305637 |